CLEC1B is a Promising Prognostic Biomarker and Correlated with Immune Infiltration in Hepatocellular Carcinoma

References

• Dawkins J, Webster RM. The hepatocellular carcinoma market. Nat Rev Drug Discov. 2019;18:13–14. doi:10.1038/nrd.2018.146
   PubMed Web of Science ®Google Scholar
• Yang JD, Hainaut P, Gores GJ, et al. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol. 2019;16:589–604. doi:10.1038/s41575-019-0186-y
   PubMed Web of Science ®Google Scholar
• Bresnahan E, Lindblad KE, Ruiz de Galarreta M, Lujambio A. Mouse models of oncoimmunology in hepatocellular carcinoma. Clin Cancer Res. 2020;26:5276–5286. doi:10.1158/1078-0432.CCR-19-2923
   PubMed Web of Science ®Google Scholar
• Llovet JM, Zucman-Rossi J, Pikarsky E, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2016;2:16018. doi:10.1038/nrdp.2016.18
   PubMed Web of Science ®Google Scholar
• Fleming BD, Urban DJ, Hall MD, et al. Engineered Anti-GPC3 Immunotoxin, HN3-ABD-T20, produces regression in mouse liver cancer xenografts through prolonged serum retention. Hepatology. 2020;71:1696–1711. doi:10.1002/hep.30949
   PubMed Web of Science ®Google Scholar
• Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet. 2018;391:1301–1314. doi:10.1016/S0140-6736(18)30010-2
   PubMed Web of Science ®Google Scholar
• Holtzhausen A, Harris W, Ubil E, et al. TAM family receptor kinase inhibition reverses mdsc-mediated suppression and augments Anti-PD-1 therapy in melanoma. Cancer Immunol Res. 2019;7:1672–1686. doi:10.1158/2326-6066.CIR-19-0008
   PubMed Web of Science ®Google Scholar
• Ruiz de Galarreta M, Bresnahan E, Molina-Sánchez P, et al. β-catenin activation promotes immune escape and resistance to Anti-PD-1 Therapy in hepatocellular carcinoma. Cancer Discov. 2019;9:1124–1141. doi:10.1158/2159-8290.CD-19-0074
   PubMed Web of Science ®Google Scholar
• Ott PA, Hodi FS, Kaufman HL, Wigginton JM, Wolchok JD. Combination immunotherapy: a road map. J Immunother Cancer. 2017;5. doi:10.1186/s40425-017-0218-5
   Web of Science ®Google Scholar
• Finn R, Ryoo B-Y, Merle P, et al. Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial. J Clin Oncol. 2020;38:193–202. doi:10.1200/jco.19.01307
   PubMed Web of Science ®Google Scholar
• Binnewies M, Roberts EW, Kersten K, et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med. 2018;24:541–550. doi:10.1038/s41591-018-0014-x
   PubMed Web of Science ®Google Scholar
• de Azevedo RA, Shoshan E, Whang S, et al. MIF inhibition as a strategy for overcoming resistance to immune checkpoint blockade therapy in melanoma. Oncoimmunology. 2020;9. doi:10.1080/2162402X.2020.1846915
   PubMed Web of Science ®Google Scholar
• Jiang Y, Zhang Q, Hu Y, et al. ImmunoScore signature: a prognostic and predictive tool in gastric cancer. Ann Surg. 2018;267:504–513. doi:10.1097/SLA.0000000000002116
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zhang Z. The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cell Mol Immunol. 2020;17:807–821. doi:10.1038/s41423-020-0488-6
   PubMed Web of Science ®Google Scholar
• Huang AC, Postow MA, Orlowski RJ, et al. T-cell invigoration to tumour burden ratio associated with anti-PD-1 response. Nature. 2017;545:60–65. doi:10.1038/nature22079
   PubMed Web of Science ®Google Scholar
• Feng Q, Chang W, Mao Y, et al. Tumor-associated macrophages as prognostic and predictive biomarkers for postoperative adjuvant chemotherapy in patients with stage II colon cancer. Clin Cancer Res. 2019;25:3896–3907. doi:10.1158/1078-0432.CCR-18-2076
   PubMed Web of Science ®Google Scholar
• Meng D, Luo M, Liu B. The role of CLEC-2 and its ligands in thromboinflammation. Front Immunol. 2021;12. doi:10.3389/fimmu.2021.688643
   Web of Science ®Google Scholar
• Ozaki Y, Tamura S, Suzuki-Inoue K. New horizon in platelet function: with special reference to a recently-found molecule, CLEC-2. Thromb J. 2016;14. doi:10.1186/s12959-016-0099-8
   PubMedGoogle Scholar
• Suzuki-Inoue K, Osada M, Ozaki Y. Physiologic and pathophysiologic roles of interaction between C-type lectin-like receptor 2 and podoplanin: partners from in utero to adulthood. J Thromb Haemost. 2017;15:219–229. doi:10.1111/jth.13590
   PubMed Web of Science ®Google Scholar
• Wang L, Yin J, Wang X, et al. C-type lectin-like receptor 2 suppresses AKT signaling and invasive activities of gastric cancer cells by blocking expression of phosphoinositide 3-kinase subunits. Gastroenterology. 2016;150:1183–1195.
   PubMed Web of Science ®Google Scholar
• Suzuki-Inoue K, Kato Y, Inoue O, et al. Involvement of the snake toxin receptor CLEC-2, in podoplanin-mediated platelet activation, by cancer cells. J Biol Chem. 2007;282:25993–26001. doi:10.1074/jbc.M702327200
   PubMed Web of Science ®Google Scholar
• Wang Y, Lv Y, Liu TS, et al. Cordycepin suppresses cell proliferation and migration by targeting CLEC2 in human gastric cancer cells via Akt signaling pathway. Life Sci. 2019;223:110–119.
   PubMed Web of Science ®Google Scholar
• Hu K, Wang Z-M, Li J-N, et al. CLEC1B expression and PD-L1 expression predict clinical outcome in hepatocellular carcinoma with tumor hemorrhage. Transl Oncol. 2018;11:552–558. doi:10.1016/j.tranon.2018.02.010
   PubMed Web of Science ®Google Scholar
• Song H, Liu Y, Li X, et al. Long noncoding RNA CASC11 promotes hepatocarcinogenesis and HCC progression through EIF4A3-mediated E2F1 activation. Clin Transl Med. 2020;10. doi:10.1002/ctm2.220
   Web of Science ®Google Scholar
• Zeineldin M, Federico S, Chen X, et al. MYCN amplification and ATRX mutations are incompatible in neuroblastoma. Nat Commun. 2020;11. doi:10.1038/s41467-020-14682-6
   PubMed Web of Science ®Google Scholar
• Rehmani H, Li Y, Li T, et al. Addiction to protein kinase Cɩ due to PRKCI gene amplification can be exploited for an aptamer-based targeted therapy in ovarian cancer. Signal Transduct Target Ther. 2020;5. doi:10.1038/s41392-020-0197-8
   PubMed Web of Science ®Google Scholar
• Molinie N, Rubtsova SN, Fokin A, et al. Cortical branched actin determines cell cycle progression. Cell Res. 2019;29:432–445. doi:10.1038/s41422-019-0160-9
   PubMed Web of Science ®Google Scholar
• Xu Q, Li Y, Gao X, et al. HNF4α regulates sulfur amino acid metabolism and confers sensitivity to methionine restriction in liver cancer. Nat Commun. 2020;11:1–7. doi:10.1038/s41467-020-17818-w
   PubMed Web of Science ®Google Scholar
• Sia D, Villanueva A, Friedman SL, Llovet JM. Liver cancer cell of origin, molecular class, and effects on patient prognosis. Gastroenterology. 2017;152:745–761. doi:10.1053/j.gastro.2016.11.048
   PubMed Web of Science ®Google Scholar
• Wang H, Lu Z, Zhao X. Tumorigenesis, diagnosis, and therapeutic potential of exosomes in liver cancer. J Hematol Oncol. 2019;12. doi:10.1186/s13045-019-0806-6
   Web of Science ®Google Scholar
• Ma W, Gilligan BM, Yuan J, Li T. Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy. J Hematol Oncol. 2016;9:47. doi:10.1186/s13045-016-0277-y
   PubMed Web of Science ®Google Scholar
• Kennedy LB, Salama AKS. A review of cancer immunotherapy toxicity. CA Cancer J Clin. 2020;70:86–104. doi:10.3322/caac.21596
   PubMed Web of Science ®Google Scholar
• Rosato PC, Wijeyesinghe S, Stolley JM, et al. Virus-specific memory T cells populate tumors and can be repurposed for tumor immunotherapy. Nat Commun. 2019;10. doi:10.1038/s41467-019-08534-1
   PubMed Web of Science ®Google Scholar
• Waks AG, Stover DG, Guerriero JL, et al. The immune microenvironment in hormone receptor-positive breast cancer before and after preoperative chemotherapy. Clin Cancer Res. 2019;25:4644–4655. doi:10.1158/1078-0432.CCR-19-0173
   PubMed Web of Science ®Google Scholar
• Tsukiji N, Inoue O, Morimoto M, et al. Platelets play an essential role in murine lung development through Clec-2/podoplanin interaction. Blood. 2018;132:1167–1179. doi:10.1182/blood-2017-12-823369
   PubMed Web of Science ®Google Scholar
• Vakkila J, Lotze MT. Inflammation and necrosis promote tumour growth. Nat Rev Immunol. 2004;4:641–648. doi:10.1038/nri1415
   PubMed Web of Science ®Google Scholar
• Yin T, He S, Liu X, et al. Extravascular red blood cells and hemoglobin promote tumor growth and therapeutic resistance as endogenous danger signals. J Immunol. 2015;194:429. doi:10.4049/jimmunol.1400643
   PubMed Web of Science ®Google Scholar
• Carr BI, Cavallini A, D’Alessandro R, et al. Platelet extracts induce growth, migration and invasion in human hepatocellular carcinoma in vitro. BMC Cancer. 2014;14. doi:10.1186/1471-2407-14-43
   Web of Science ®Google Scholar
• Murciano-Goroff YR, Warner AB, Wolchok JD, et al. The future of cancer immunotherapy: microenvironment-targeting combinations. Cell Res. 2020;30:507–519. doi:10.1038/s41422-020-0337-2
   PubMed Web of Science ®Google Scholar
• Bagchi S, Yuan R, Engleman EG, et al. Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance. Annu Rev Pathol. 2021;16:223–249. doi:10.1146/annurev-pathol-042020-042741
   PubMed Web of Science ®Google Scholar